论文部分内容阅读
西拉普利是一种新的非巯基血管紧张素转化酶(ACE)抑制剂,是用计算机设计的一个对靶酶具有高特异性、高选择性的化合物。它已在4000余例不同程度的高血压病人上研究,像老年高血压、肾型高血压,还包括充血性心力衰竭或慢性阻塞性肺病患者。每天用一次就有降压作用。患者对该药的耐受性类似于其他降压药,如缓释的普萘洛尔、依那普利、卡托普利等。近期研究证明,西拉普利不仅有降压作用,而且可减缓被损伤血管的增殖反应。
Cilazapril, a novel non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, is a computer-designed compound with high specificity and selectivity for target enzymes. It has been studied in more than 4000 patients with varying degrees of hypertension, such as hypertension in the elderly, renal hypertension, including patients with congestive heart failure or chronic obstructive pulmonary disease. Once a day with antihypertensive effect. Patient tolerance to the drug is similar to other antihypertensive drugs, such as sustained-release propranolol, enalapril, captopril and others. Recent studies have shown that cilazapril not only has antihypertensive effect, but also slowed the proliferation of vascular injury.